No Data
Insiders At Y-mAbs Therapeutics Sold US$4.5m In Stock, Alluding To Potential Weakness
While Shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Y-mAbs Therapeutics Signs Lease Deal for New Jersey Property
Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)
Y-mAbs Therapeutics Price Target Maintained With a $23.00/Share by Wedbush